Literature DB >> 10709854

Preeclampsia: what we know and what we do not know.

J M Roberts1.   

Abstract

Preeclampsia remains a major health problem for mothers and infants. Studying the entire pathophysiology of preeclampsia rather than "pregnancy-induced hypertension" has greatly expanded our knowledge of the disorder. Current thinking approaches preeclampsia as a 2 stage disorder: reduced placental perfusion usually secondary to abnormal implantation and a consequent maternal disorder characterized by endothelial dysfunction and subsequent pathophysiological changes. We know much about the 2 stages and less about their linkage. It is evident that reduced placental perfusion is not sufficient to account for the pathophysiology. Reduced perfusion and abnormal implantation occur in other conditions (intrauterine growth restriction and preterm labor) without the maternal syndrome. This leads to the hypothesis that reduced placental perfusion must interact with maternal constitutional factors to generate the systemic pathophysiology of preeclampsia. The similarities of these risk factors and metabolic alterations between preeclampsia and atherosclerosis suggest a common pathophysiology. Oxidative stress is postulated as the genesis of endothelial dysfunction in atherosclerosis. The author proposes that oxidative stress secondary to reduced placental perfusion leads to endothelial dysfunction, linking the 2 stages of the syndrome.

Entities:  

Mesh:

Year:  2000        PMID: 10709854     DOI: 10.1016/s0146-0005(00)80050-6

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  31 in total

1.  Protein composition of microparticles shed from human placenta during placental perfusion: Potential role in angiogenesis and fibrinolysis in preeclampsia.

Authors:  S Guller; Z Tang; Y Y Ma; S Di Santo; R Sager; H Schneider
Journal:  Placenta       Date:  2010-11-11       Impact factor: 3.481

Review 2.  Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia.

Authors:  Yang Xia; Susan M Ramin; Rodney E Kellems
Journal:  Hypertension       Date:  2007-06-18       Impact factor: 10.190

3.  Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study.

Authors:  Anne Lise Brantsaeter; Ronny Myhre; Margaretha Haugen; Solveig Myking; Verena Sengpiel; Per Magnus; Bo Jacobsson; Helle Margrete Meltzer
Journal:  Am J Epidemiol       Date:  2011-08-05       Impact factor: 4.897

4.  Vitamin D improves the angiogenic properties of endothelial progenitor cells.

Authors:  M Grundmann; M Haidar; S Placzko; R Niendorf; N Darashchonak; C A Hubel; F von Versen-Höynck
Journal:  Am J Physiol Cell Physiol       Date:  2012-08-29       Impact factor: 4.249

5.  New-onset maternal gestational hypertension and risk of retinopathy of prematurity.

Authors:  Mohamed A Zayed; Abhineet Uppal; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-12       Impact factor: 4.799

6.  Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses.

Authors:  D M Adelman; M Gertsenstein; A Nagy; M C Simon; E Maltepe
Journal:  Genes Dev       Date:  2000-12-15       Impact factor: 11.361

Review 7.  Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy.

Authors:  Douglas M Woudstra; Sue Chandra; G Justus Hofmeyr; Therese Dowswell
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

8.  Maternal angiotensinogen (AGT) haplotypes, fetal renin (REN) haplotypes and risk of preeclampsia; estimation of gene-gene interaction from family-triad data.

Authors:  Hege K Vefring; Line Wee; Astanand Jugessur; Håkon K Gjessing; Stein T Nilsen; Rolv T Lie
Journal:  BMC Med Genet       Date:  2010-06-10       Impact factor: 2.103

Review 9.  Angiotensin receptors, autoimmunity, and preeclampsia.

Authors:  Yang Xia; Cissy Chenyi Zhou; Susan M Ramin; Rodney E Kellems
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

10.  Maternal serum ischemia modified albumin as a marker for hypertensive disorders of pregnancy: a pilot study.

Authors:  Sapna Vyakaranam; Aparna Varma Bhongir; Dakshayani Patlolla; Rekha Chintapally
Journal:  Int J Reprod Contracept Obstet Gynecol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.